Callan Capital’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Callan Capital’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,333	Closed	-$37K	–	134
2021 Q3	$37K	Hold	3,333	–	–	0.01%	86
2021 Q2	$57K	Hold	3,333	–	–	0.01%	87
2021 Q1	$88K	Hold	3,333	–	–	0.02%	84
2020 Q4	$121K	Hold	3,333	–	–	0.02%	81
2020 Q3	$118K	Hold	3,333	–	–	0.03%	78
2020 Q2	$142K	Buy	+3,333	New	+$225K	0.04%	85

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Callan Capital's EVFM Position: Q4 2021 in Review

Callan Capital sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 3,333 shares — an estimated $37K sold.

Callan Capital first reported a position in EVFM in Q2 2020 and held it in 6 quarters. The position peaked at $142K in Q2 2020. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

Callan Capital reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Callan Capital sold 3,333 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $37K.
Callan Capital first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Callan Capital's Evofem Biosciences, Inc. Common Stock position peaked at $142K in Q2 2020.
62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Callan Capital's 13F filing for Q4 2021, filed 21 Jan 2022.